Drug pricing is at the forefront of U.S. health policy and a topic of interest at the federal and state level. In the second installment of a three-part series in Law360 on drug pricing reform, health care partner Deborah Kantar Gardner and counsel Peter Holman Jr. review the status of key state drug pricing reforms, where some of the more immediate impacts of drug pricing are occurring.
The authors analyzed four common state initiatives: drug pricing transparency; pharmacy benefit manager controls; drug importation; and value-based arrangements.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.